We had previously described the leucine-rich acidic nuclear protein (LANP) as a candidate mediator of toxicity in the polyglutamine disease, spinocerebellar ataxia type 1 (SCA1). This was based on the observation that LANP binds ataxin-1, the protein involved in this disease, in a glutamine repeat dependent manner. Furthermore, LANP is expressed abundantly in purkinje cells, the primary site of ataxin-1 pathology. Here we focused our efforts on understanding the neuronal properties of LANP. In undifferentiated neuronal cells LANP is predominantly a nuclear protein, requiring a bona-fide nuclear localization signal, to be imported into the nucleus.
INTRODUCTION
Spinocerebellar ataxia type 1 (SCA1) belongs to a group of disorders in which a polyglutamine expansion in the disease protein launches a cascade of events that causes relentless neurodegeneration. We had previously speculated that the Leucine-rich Acidic Nuclear Protein (LANP) stands out as a particularly appealing candidate mediator of toxicity in SCA1 based on its ability to interact with ataxin-1 in a glutamine repeat dependent manner (1) .
Moreover, LANP is expressed at particularly high levels in purkinje cells, the seat of SCA1 pathology. Thus one could envisage a scenario where LANP's functions could be altered upon binding to ataxin-1, triggering downstream toxic events. This could also account for the regional toxicity of ataxin-1, despite its own ubiquitous expression.
Since its first description in 1994, LANP has been implicated in myriad cellular functions from the cell surface to the nucleus. First described as an HLA-associated protein (and hence called PHAPI or putative HLA associated protein I), it was suspected to be involved in signal transduction in lymphocytes (2) . Matsuoka et al. (1994) independently described this protein in the developing cerebellum, and noting that it contained a leucine-rich repeat, called it by the acronym LANP. With a modular architecture reminiscent of a tadpole, LANP consists of a globular head formed by the N-terminal leucine-rich domain containing five leucine-rich repeats (LRR), and a C-terminal tail formed by the remaining length of acidic residues (3). As such, it belongs to a large and very interesting family of proteins that contain leucine-rich regions (LRRs) crucial for protein interactions, by forming a very characteristic secondary structure designed for protein-protein interactions (4) (5) (6) . It was therefore speculated to be a modulator of signaling pathways in cerebellar morphogenesis. 4 dependent localization of the Golgi apparatus in semi-intact cells (15, 16) . Since it is unclear which of LANP's functions, if any, might be perturbed in SCA1 pathogenesis, we sought to understand the neuronal properties of LANP.
Here we report that LANP is typically nuclear in undifferentiated neuro2a cells. This compartmentalization is dependent on a nuclear localization signal in its C terminal domain.
LANP tends to be drawn to the cytoplasm during the process of neuronal differentiation.
Intriquingly, in a search for LANP interacting proteins, we have identified the microtubuleassociated protein, MAP1B, as a cytoplasmic protein that interacts with LANP. This interaction occurs via its light chain. Moreover the effects of MAP1B on neurite extension are altered by its interaction with LANP. This interaction has the potential to not only modulate neuritogenesis during neuronal development, but could also contribute to the loss of neurites, and cytoarchitectural disarray seen in SCA1.
EXPERIMENTAL PROCEDURES
Yeast two-hybrid plasmids and yeast strains. Full-length mouse LANP c-DNA was subcloned into the Nco1-Sma1 sites of the yeast two-hybrid bait plasmid pGBKT7 and the plasmid DNA was transformed into yeast strain AH109 (Clontech, CA). Transformed AH109 yeast strains containing the LANP bait plasmid were mated to the Y187 yeast strain pretransformed with a mouse brain pACT2 library. We used high stringency auxotrophic selection (using media deficient in adenine and histidine) to select for interacting clones. Positive clones were also tested for beta galactosidase activity in an overlay assay for the interaction of the bait and prey (library clone) interactions independently.
To delimit the region of interaction of LANP we generated N-and C-terminally deleted LANP constructs. The C-terminally deleted LANP construct was engineered by digesting pGBK-T7 LANP with Bsm1-Sma1 to remove the C-terminal acidic domain, preserving the complete LRR region and then religating the backbone. To generate the N-terminally deleted construct we used a PCR-based strategy to clone a truncated LANP (residues 129-247) into the Nde1-Sma1 sites of pGBK-T7.
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Cell culture, transfection, expression constructs, and immunofluorescence. Clones derived from the pACT2 yeast two-hybrid screen were subcloned into the mammalian expression vector pCMV-HA (Clontech). The construction of the mammalian tet-responsive expression plasmids (pMT5tet and pMT17tet) containing the heavy chain and full-length clones of rat MAP1B tagged at their C-terminal ends to the myc epitope has been described (17) . The nuclear localization signal mutants of LANP were constructed by a PCR based mutagenesis strategy so as to alter residues 236 and 237 to alanine residues (from lysine and argine respectively) followed by subcloning into pCMV-myc (Clontech).
Tissue culture cells were obtained from American Type Tissue Collection (Manassas, VA). Neuro-2a was used as a prototypical neuronal cell line. Differentiation of neuro2a cells was performed by growing cells in serum-free medium (Optimem, Gibco) containing 0.3 mM dbcAMP (18) . For experiments on non-neuronal cells, COS-7 cells or BHK-21 (kind gift of Dr.
O. Skalli, Univ. of Illinois) cells were used. To quantify neuritogenesis, cells were counted as having extended neurites if they exhibited at least one process longer than two cell bodies in length.
Transfections were performed on coverslips using the lipofectamine plus reagent (GIBCO, BRL). Cells were fixed 48 hours post-transfection before being processed for immunofluorescence (17) . All images were captured by either light, or confocal laser-scanning microscopy (Zeiss). Images were manipulated using Adobe Photoshop 5.0.
Antibodies. Anti-LANP antibody (antibody 3118) was generated by immunizing goat with bacterially expressed full-length LANP as a GST fusion protein expressed and purified after subcloning into the bacterial expression vector pGEX5X3 (Pharmacia/LKB Biotechnology).
Anti-MAP1B C-20 Ab recognizes the light chain of MAP1B (Santacruz). The following antibodies to epitope tags were used: anti-myc epitope-clone 9E10 (Sigma); anti FLAG-clone m2 or polyclonal F7425 (Sigma), and anti HA-clone HA .11 (Covance); dilutions of 1:100 for immunofluorescence and 1:1000 for western blotting.
expressed as a FLAG-tagged fusion in pFLAG CMV-2. Two days post-transfection cells were washed twice with PBS, then lysed in 3 ml lysis buffer: PBS, 0.5% NP40, 5mM EDTA and protease inhibitors (COMPLETE, Roche) using the protocol recommended in the antibodies protocol guide using the relevant antibody or non-specific immunoglobulins as controls (Clontech). Anti HA IP was performed with anti HA beads (Sigma); anti LANP IP was performed by protein G beads coupled to FLAG M2 and 3118.
RESULTS
LANP is a nucleo-cytoplasmic shuttling protein that translocates from the nucleus to the cytoplasm upon differentiation.
LANP has been described as both a nuclear and a cytoplasmic protein (1, 16, 19) . Brennan et al. had earlier shown than in non-neuronal Hela cells, LANP is a nucleocytoplasmic shuttling protein that interacts with the nuclear export factor CRM1, presumably via its leucine rich domains, two of which are consensus sequences for the leptomycin sensitive nuclear export signals (NES), seen in rev and other shuttling proteins (19, 20) . Although it is not possible to mutate these putative nuclear export signal regions without affecting the conserved leucine rich domains, the defining feature of the family of LRR proteins (6) , the existence of these export signals seems likely based on the ability of leptomycin B to inhibit shuttling of LANP. LANP also bears a putative nuclear localization signal (NLS) in its C terminal acidic domain. This is a four amino acid stretch of basic residues seen in LANP spanning residues 234 to 237 (lysinearginine-lysine-arginine). In a mouse LANP-like protein, this sequence when tagged to green fluorescent protein (GFP) is sufficient to induce the nuclear localization of GFP suggesting that this stretch of amino acids can function as an NLS (21) . To test whether this sequence is indeed the NLS for LANP and whether these residues are necessary for LANP's nuclear localization we mutated the second lysine and arginine residues of the this quartet to alanine residues. This mutant form of LANP (henceforth called LANP-KRAA) remains cytoplasmic even when coexpressed with wild type LANP (that remains predominantly nuclear) (Figure 1 ). This experiment also demonstrates the inability of mutant LANP to piggy-back on its wild type 7 counterpart and enter the nucleus. Such a scenario might have been expected based on LANP's ability to self associate existing as dimers and trimers as has been previously reported (16) .
Since LANP is a developmentally regulated protein in neuronal cells, with maximum abundance in the early postnatal life, we sought to determine whether its localization is altered depending on the process of differentiation, as has been observed for other proteins expressed at high levels during development (22, 23) . In undifferentiated neuro2a cells, LANP typically is nuclear with little cytoplasmic staining. Upon differentiation by dbcAMP in the presence of low serum (18) , LANP tends to be diffuse cytoplasmic, particularly in those cells with the most extensive neurites (Figure 2 , top panel). In addition to staining endogenous LANP with an LANP specific antibody, we also transfected epitope-tagged LANP into neuro2a cells so as to follow localization by an antibody specific to the epitope tag to rule out the possibility of nonspecific staining. Immunofluorescence microscopy once again revealed a dramatic alteration in 
LANP interacts with MAP1B
To further delineate the neuronal properties of LANP, we decided to search for LANP interacting proteins expressed in neurons. To this end we performed a yeast two-hybrid screen using a mouse brain library and full length LANP as bait. We identified MAP1B as a potential interacting partner. Three representative library clones of MAP1B that were fished out by the two-hybrid screening are shown in the schematic in relationship to the sequence of the rat MAP1B construct (Fig 3A) . We also pulled out several clones corresponding to the C terminal domain of MAP1A. These interacting clones were in general short. This result was not surprising in view of the fact that MAP1B and A share extensive similarity in their primary structure (80% identity in their last 100 amino acids). Intriguingly we also identified a tau isoform (accession number U12916) as an interacting bait. Since LANP had been demonstrated to interact with tau in biochemical assays we did not pursue LANP's interaction with tau (15, 16, 24) . Of our microtubule associated interactors, we decided to pursue the MAP1B interaction further, as it would indicate that LANP has the intriguing property of binding to all classes of structural microtubule-associated proteins.
MAP1B, along with MAP1A constitute the family of large molecular weight microtubule-associated proteins. Both these proteins have shared domains in addition to the Cterminal tail, some of which contain canonical repeats (Lys-Lys-Glu-X) involved in binding to microtubules (25, 26) . The proteins are also processed similarly, undergoing proteolytic cleavage of a single precursor to produce a light chain and a heavy chain (27, 28) . In the case of MAP1B the heavy chain is 243 kD, while the light chain is 27 kD; the cleavage site has been narrowed to within 40 residues of a proline-rich hydrophobic domain of the full-length MAP1B (29) . One of our clones (clone 3-87; 242 residues) corresponded almost exactly to the complete light chain of MAP1B, beginning four residues downstream from the predicted cleavage event. This clone was the strongest interactor in our yeast two-hybrid screen, interacting more robustly with LANP than the other MAP1B clones picked up in the yeast two-hybrid that were either longer (clone 3-75, 559 residues) or shorter (clone 3-3, 168 residues) than the light chain. This suggests that LANP binds to the light chain per se ( Figure 3A ).
Since we were keen to determine which domain of LANP, mediates LANP's interaction with MAP1B, we generated N-and C-terminal deletions of LANP. Using yeast two-hybrid assays we were able to demonstrate that LANP's acidic C-terminal domain interacted more robustly with the light chain of MAP1B than did LANP's N-terminal domain, the domain bearing the LRRs (Fig 3B) . Incidentally, it is the C terminal domain that bears the nuclear localization signal. It should be mentioned in the context of discussing LANP's domain structure that it is the N-terminal region, i.e., the leucine-rich region, that is responsible for LANP's interaction with ataxin-1 (1).
LANP interacts with the light chain of MAP1B in vivo
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Since the majority of the MAP1B fragments isolated by the yeast two-hybrid screen correspond to the C-terminal domain of the MAP1B precursor that eventually becomes the light chain, we sought to test the idea that the interaction of LANP is specific to MAP1B's light chain.
We first performed immunfluorescence studies to look at the subcellular localization of LANP in the presence of the MAP1B light chain (Fig 4) . When transfected alone, LANP localized predominantly to the nucleus in approximately 80% of the cells. In the small percentage of cos-7 cells in which LANP is cytoplasmic, the staining is either diffuse or slightly vesicular, as was reported for CHO cells (Figure 4 panel A) (16) . Incidentally, in our own studies using CHO cells, we found that LANP (transfected or endogenous) displays a predominant nuclear staining in addition to the lower intensity cytoplasmic staining (data not shown). Discrepancy with earlier findings might relate to the fact that the antibody used by When co-tranfected with the MAP1B light chain, however, LANP relocated to the cytoplasm in approximately 80% of cos-7 cells. This relocation to the cytoplasm was dramatic and in most of the cells LANP tends to be diffuse and cytoplasmic. However, in a few cells the LANP distribution was clearly fibrillar, with both MAP1B and LANP, colocalizing in a perinuclear filamentous pattern. This pattern reflects the bundled and collapsed microtubule networks described during earlier studies on its role in organizing tubulin networks (17 and our own data not shown using anti-tubulin antibodies) (Fig 4) . This suggests not only that the light chain of MAP1B interacts with LANP, but that LANP can bind at least to some extent with the microtubule-bound pool of the MAP1B light chain. In undifferentiated neuro2a cells this relocation to the cytoplasm is even more dramatic with more than 90% showing a cytoplasmic distribution of LANP when MAP1B light chain is overexpressed, reminiscent of the translocation of LANP seen during the process of differentiation.
We next sought co-immunoprecipation (IP) evidence. In Figure 4H we demonstrated that we can co-IP the MAP1B light chain using antibodies targeted to LANP; and also in the reverse direction, ie. co-IP LANP when using antibodies directed against MAP1B light chain. The interaction between the two is thus fairly robust.
Finally, to determine whether LANP's preference for the light chain holds in cells, we used tagged constructs of MAP1B corresponding to the full-length precursor and the heavy chain of rat MAP1B (approximately 95% identity to mouse MAP1B) (Fig 5 schematic) and transfected cells with FLAG LANP along side either full length MAP1B or just with its heavy chain. We discovered that, much like the light chain of MAP1B, full-length MAP1B also causes a dramatic shift of staining from the nucleus to the cytoplasm, with a majority of cells (close to 70%) showing a cytoplasmic staining (Fig 5) . This was to be expected, since full-length MAP1B is cleaved into its heavy and light chain in both neuronal and non-neuronal cells (17 and data not shown). In contrast, expressing the heavy chain alone causes a less dramatic transition from nuclear to cytoplasmic staining, although it did increase the total number of cells showing a cytoplasmic staining from approximately 20% to 40%. We speculate that this increase might be due to alterations in the dynamics of the endogenous light chain caused by the abundant quantities of newly introduced heavy chain although it is possible that there is an interaction albeit less robust with the heavy chain as well. This is conceivable since the heavy chain contains a microtubule binding domain consisting of several KKEX and KKEE motifs, thought to contribute basic properties to the heavy chain and that could also potentially interact with the acidic tail domain of LANP (25).
LANP modulates MAP1B's functions in neuritogenesis
Recent evidence suggests that the ratio of light chain to heavy chain is under strict developmental control, mediated by differential proteolysis and clearance of these fragments to keep the light and heavy chains in a 6:1 to 8:1 molar ratio (30). We therefore tested whether different fragments of MAP1B might have differential effects on neurite outgrowth in neuro2a cells and whether LANP's binding to the light chain could thereby affect neuritogenesis.
Full-length MAP1B, the light chain and the heavy chain each had a different effect on the ability of neuro2a cells to extend neurites (Fig 6) . Although full-length MAP1B has been previously shown to have only modest effects on microtubule stability in non-neuronal cells (31, 32) , it dramatically altered the morphology of transfected neuro2a cells. These cells became rounded (more than 80%) and were incapable of spreading out or extending neurites even after stimulation with dbcAMP, a potent inducer of neuritogenesis (up to 4 days after induction).
Neither the light chain nor the heavy chain alone had such a significant effects on neuritic morphology ( Fig 6) ; although we noticed that the heavy chain had a greater inhibitory effect on neuritogenesis when compared to the light chain (80% and 60% of cells transfected with the light or heavy chain, respectively, were able to extend neurites). Thus it appears that both the light chain and the heavy chain are presumably required to stabilize the microtubule cytoskeleton at the expense of neuritogenesis.
This inhibitory effect on neuritogenesis by full length MAP1B now allowed us to test whether LANP modulates the ability of full-length MAP1B to suppress neurite formation induced by dbcAMP (Fig 7) . Co-transfecting LANP with full-length MAP1B significantly increased the cells' ability to form neurites. On the other hand, LANP did not affect the ability of cells to express neurites when transfected with either the heavy chain or light chain alone, suggesting that the alleviation on the inhibition of neuritogenesis is because of its interaction with the MAP1B complex.
Discussion
Although it is clear that SCA1 is caused by an expansion of glutamine repeats in the disease-causing protein ataxin-1, precisely how this repeat expansion translates into neurotoxic events is still an unanswered question. The experiments in this study were driven by the rationale that understanding the interactions and functions of proteins that may be sequestered by ataxin-1 might point to possible candidate toxic scenarios. LANP is one such ataxin-1 interacting protein, that interacts more strongly with mutant ataxin-1 than its wild type counterpart; is expressed at higher levels in neurons that tend to be affected in SCA1; and, has been shown to be redistributed into ataxin-1 inclusions (1). We therefore sought to identify LANP's neuronal properties as a first step toward understanding its possible role in SCA1 pathogenesis. We found that, during neuronal differentiation, LANP translocates from the nucleus to the cytoplasm, where at least one of its interacting proteins is the light chain of MAP1B. Moreover LANP influences the modulatory role of MAP1B on neurite extension.
These results immediately suggest a role for LANP during neuronal development when neurite extension occurs. But these experiments, although not directly implicating LANP in SCA1 pathology, also suggest the tantalizing possibility that ataxin-1 could affect cytoskeletal functions by disrupting the function of microtubule associated proteins via the intermediary LANP. The MAP1 proteins and neurological disease MAP1B and MAP1A constitute the family of heavy molecular weight Type I microtubule-associated proteins. Both are expressed at high levels in the nervous system (33, 34) , bind the acidic domain of tubulin with similar repeat sequences (Lys-Lys-Glu-X), and have several areas of homology in their primary structure (27, 28) . The two proteins are reciprocally expressed over the lifespan of an organism, with MAP1B being expressed earlier during development, at a time when the cytoskeleton is quite dynamic. MAP1A typically is expressed later when MAP1B is down regulated, and is believed to confer stability to extended neurites (35) (36) (37) (38) (39) (40) (41) .
Of the two microtubule-associated proteins MAP1A and B, the latter is better studied.
Depleting MAP1B either by anti-sense approaches or by injecting antibodies prevents neurite outgrowth in tissue-culture cells (42, 43) . In Drosophila complete loss of MAP1B function Intriguingly, MAP1B has been implicated in neuronal pathology in genetic diseases in mouse and man. In the fly, the fragile X-related gene (FMRP) appears to be a translational repressor of the MAP1B homolog, suggesting that MAP1B levels are dysregulated in human fragile X syndrome (48) . These findings are consistent with microarray studies that identified MAP1B as an FMRP RNA target (49, 50) . Perhaps the most compelling evidence that MAP1B, and particularly its light chain, is a hub for interactions with disease-causing proteins is the finding that the light chain of MAP1B interacts with gigaxonin, a protein that displays mutations in giant axonal neuropathy. This progressive, autosomal recessive disease afflicts the central and peripheral nervous systems and is characterized by aggregation of cytoskeletal components, particularly intermediate filaments, to such an extent as to cause an increase in axonal diameter (51) . Surprisingly MAP1B has been implicated not just in these diseases that have onset early in life, but also in adult onset neurodegeneration including Alzheimer's disease and Lewy body Parkinsonism (52,53).
As noted above, there are several levels of regulation of the MAP1 complex. Both MAP1A and B are cleaved to form a light and a heavy chain, both of which have microtubulebinding domains (17, 25, 26) ; the heavy chain is also phosphorylated (32, 43, (54) (55) (56) (57) . The light chains of MAP1B (also known as LC1) and MAP1A (also called LC2), share extensive similarity in their primary structure and are thought to be interchangeable with regard to their ability to interact with either of the heavy chains in the heavy molecular weight MAP complex (40) . There is a third light chain, LC3, that is transcribed independently from a distinct genetic locus and can also interact with either heavy chain (58), although its contribution to the stability of tubulin networks is not yet clear.
LANP: another level of regulation for MAP1B
Our findings suggest that there is another level of regulation of the MAP1B complex mediated by LANP that stems from the differential effects of the heavy chain, the light chain, and their precursor on the ability of neurons to extend neurites. Transfection of either the heavy chain or light chain alone allows neurite extension, but overexpression of full-length MAP1B inhibits neurite outgrowth. It is this inhibition that can be significantly relieved by cotransfecting LANP. The simplest interpretation of our findings might be that LANP binds to the light chain of MAP1B in the complex, thereby allowing greater flexibility of the neuronal cytoskeleton and thus neurite outgrowth. Consistent with this model is the finding that LANP does not modulate neurite outgrowth in the presence of either heavy or light chain in isolation, presumably because either chain alone would not have the stabilizing properties of a fully functional MAP1 complex.
We have also tried to test for a more direct role for LANP in regulating the effect of MAP1B on neuritogenesis. Using the microtubule depolymerizing agent nocodazole we tested whether the normally stabilizing role of the light chain of MAP1B light chain described previously (17) can be altered by LANP. We could not however detect a major effect on microtubule networks (data not shown), although we cannot rule out the possibility that subtle effects on microtubule stability might only be evident in neurons over a prolonged period of time. We also sought to test the possibility that LANP binds to the full length precursor regulating the endoproteolysis of the MAP1B precursor. We could not however quantify any significant alterations in the ratios of light chain to heavy chain in the presence and absence of LANP (data not shown).
Our results extend the results of Pfeffer and coworkers, who identified LANP as a modulator of microtubule-associated proteins, earning it the moniker mapmodulin (15, 16, 24) . In their experiments they demonstrated that LANP binds to the free subunits of the structural MAPS, MAP2, and Tau and to the non-neuronal MAP, MAP4. Since LANP enhances vesicle transport, they hypothesized that LANP clears the microtubule tracks from associated proteins.
Our findings indicate that LANP has the remarkable property of binding to all classes of structural MAPs-both the tau family of heat-stable MAPs (that also includes MAP2 and 4) and the high molecular weight heat-labile family represented by MAP1A and B-making LANP a potentially important regulator of microtubule function. The domain crucial for this interaction is the C-terminal domain of LANP that is rich in acidic residues and strikingly similar to the Cterminus of tubulin that suggests a model where LANP and tubulin compete for MAPs (15) .
These results are in general consistent with such a model, although in a few cells LANP and MAP1B clearly display a microtubular pattern suggesting that LANP/MAP1B light chain complexes can in some instances still associate with the microtubule network. Additionally this acidic domain is shared by a variety of proteins, including closely related leucine-rich family members such as APRIL and PAL31 that might also be implicated in similar functions (59, 60) . It is an intriguing possibility that this family of proteins might have distinct effects on cytoskeletal behavior and possess functions specific to different cell types and developmental time courses.
LANP: neuronal development and neurological disease
The role of LANP as a modulator of microtubule-associated proteins clearly has specific implications for neuronal development. LANP expression peaks during early postnatal life at a time when brain architecture is still being formed. But in addition to its role in development, LANP and MAP interaction could also be important for the neurodegenerative events in SCA1.
Before the present studies, there had been no apparent link between the obvious neuritic pathology and the equally obvious nuclear events such as ataxin-1 accumulation. We speculate that mutant ataxin-1 binds to LANP in the nucleus, compromising LANP's interactions with its cytoplasmic partners, i.e., MAPs, and the absence of these microtubule-stabilizing interactions leads to cytoskeletal derangements or abnormalities in subcellular trafficking. This is not only reminiscent of the havoc wrought in the hereditary tauopathies and Alzheimer's disease, where the MAP, Tau is implicated, but is also in keeping with the finding that MAP1B might be directly involved in the cytoskeletal derangements of giant axonal neuropathy (Ding et al. 2002) .
This raises the possibility that alteration of MAP behavior may be common to many neurodegenerative disorders, including SCA1. Indeed, these dystrophic changes of neurites are strikingly evident using antibodies to MAP1 light chain in SCA1 mouse models (data not shown). Moreover, with MAPs playing a pivotal role in modulating tubulin networks, LANP could be involved in a variety of microtubule-based functions, including maintaining cellular morphology, regulating the movement of mitochondria, lysosomes, peroxisomes and vesicles, and in addition helping to maintain the integrity of the endoplasmic reticulum and the localization of messenger RNA (61) (62) (63) (64) (65) (66) (67) (68) . By engineering mice lacking LANP it should be possible to test for a role of LANP in neuronal development and/or SCA1 pathogenesis. 
